Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

http://ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-newsArticle&ID=2383313

BEGIN logo

JOIN OUR MAILING LIST